Keros Therapeutics exceeds enrollment target in TROPOS Trial

Keros Therapeutics (NASDAQ:KROS) has successfully completed enrollment for its Phase 2 TROPOS clinical trial, assessing the efficacy of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension.

A total of 113 patients were enrolled in the TROPOS trial, surpassing the initial target of 90 patients.

Pulmonary arterial hypertension is a rare but potentially life-threatening condition characterized by elevated blood pressure in the pulmonary arteries.

PAH can lead to shortness of breath, fatigue, chest pain, and even death.

This positive enrollment outcome reflects the significant unmet medical need for new treatment options for PAH.

The company expects to present topline data in the second quarter of 2025.